SXSW 2025
RNA: The key to Disease X prep, cancer vaccines, & beyond
Description:
SARS-CoV-2 introduced the world to mRNA vaccines. But the notion of RNA therapeutics is hardly new; in fact, it pre-dates the end of World War II. Now, in a COVID-endemic world, RNA therapeutics are poised to take off, altering the way we think about & treat disease — & potentially lowering the cost of medicine. Why the field holds the key to an even tighter turn-around for the next pandemic's vaccine; preventing the recurrence of cancer; helping humanity dodge looming scourges like the H5N1 avian flu; remedying rare disease; & even managing chronic conditions like heart disease & dementia.
Related Media
Takeaways
- SARS-CoV-2 introduced the world to mRNA vaccines, but the notion of RNA therapeutics is hardly new. It pre-dates the end of World War II.
- Now, in a COVID-endemic world, RNA therapeutics are poised to take off.
- The field holds the key to an even tighter turn-around for the next pandemic's vaccine; preventing recurrence of cancer; & treating chronic disease.
Speakers
- Dr. Eugene Yeo, Director, Sanford Stem Cell Innovation Center, University of California San Diego
- Kristen Dahlgren, Founder/CEO, Cancer Vaccine Coalition
- Stanley Crooke, M.D., Ph.D., Founder/CEO, n-Lorem Foundation
- Gilles Besin, Ph.D., Chief scientific officer, Orbital Therapeutics
Organizer
Erin Prater, Senior science writer, Sanford Stem Cell Institute at UC San Diego
SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.
Add Comments